Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial

被引:20
作者
Kjelby, Eirik [1 ]
Jorgensen, Hugo A. [2 ]
Kroken, Rune A. [1 ]
Loberg, Else-Marie [1 ,3 ]
Johnsen, Erik [1 ,2 ]
机构
[1] Haukeland Hosp, Div Psychiat, Sandviken, Sweden
[2] Univ Bergen, Dept Clin Med, N-5020 Bergen, Norway
[3] Univ Bergen, Inst Biol & Med Psychol, N-5020 Bergen, Norway
来源
BMC PSYCHIATRY | 2011年 / 11卷
关键词
2ND-GENERATION ANTIPSYCHOTICS; CHRONIC-SCHIZOPHRENIA; NEUROPSYCHOLOGICAL STATUS; REPEATABLE BATTERY; 1ST-EPISODE SCHIZOPHRENIA; ATYPICAL ANTIPSYCHOTICS; BIPOLAR DEPRESSION; CLINICAL-TRIALS; SCREENING-TEST; SYMPTOMS;
D O I
10.1186/1471-244X-11-145
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Efficacy studies indicate anti-depressive effects of at least some second generation antipsychotics (SGAs). The Bergen Psychosis Project (BPP) is a 24-month, pragmatic, industry-independent, randomized, head-to-head comparison of olanzapine, quetiapine, risperidone and ziprasidone in patients acutely admitted with psychosis. The aim of the study is to investigate whether differential anti-depressive effectiveness exists among SGAs in a clinically relevant sample of patients acutely admitted with psychosis. Methods: Adult patients acutely admitted to an emergency ward for psychosis were randomized to olanzapine, quetiapine, risperidone or ziprasidone and followed for up to 2 years. Participants were assessed repeatedly using the Positive and Negative Syndrome Scale -Depression factor (PANSS-D) and the Calgary Depression Scale for Schizophrenia (CDSS). Results: A total of 226 patients were included. A significant time-effect showing a steady decline in depressive symptoms in all medication groups was demonstrated. There were no substantial differences among the SGAs in reducing the PANSS-D score or the CDSS sum score. Separate analyses of groups with CDSS sum scores > 6 or <= 6, respectively, reflecting degree of depressive morbidity, revealed essentially identical results to the primary analyses. There was a high correlation between the PANSS-D and the CDSS sum score (r = 0.77; p < 0.01). Conclusions: There was no substantial difference in anti-depressive effectiveness among olanzapine, quetiapine, risperidone or ziprasidone in this clinically relevant sample of patients acutely admitted to hospital for symptoms of psychosis. Based on our findings we can make no recommendations concerning choice of any particular SGA for targeting symptoms of depression in a patient acutely admitted with psychosis.
引用
收藏
页数:10
相关论文
共 48 条
[1]   A DEPRESSION RATING-SCALE FOR SCHIZOPHRENICS [J].
ADDINGTON, D ;
ADDINGTON, J ;
SCHISSEL, B .
SCHIZOPHRENIA RESEARCH, 1990, 3 (04) :247-251
[2]   Depression in people with first-episode schizophrenia [J].
Addington, D ;
Addington, J ;
Patten, S .
BRITISH JOURNAL OF PSYCHIATRY, 1998, 172 :90-92
[3]   Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia [J].
Addington, Donald E. ;
Mohamed, Somaia ;
Rosenheck, Robert A. ;
Davis, Sonia M. ;
Stroup, Thomas Scott ;
McEvoy, Joseph P. ;
Swartz, Marvin S. ;
Lieberman, Jeffrey A. .
JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (01) :75-80
[4]  
[Anonymous], INT STAT CLASSIFICAT, DOI DOI 10/2016/EN#/F64
[5]  
[Anonymous], CALGARY DEPRESSION S
[6]  
[Anonymous], ATC DDD INDEX
[7]  
[Anonymous], PRACTICE GUIDELINES
[8]  
[Anonymous], COCHRANE HDB SYSTEMA
[9]   A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression [J].
Calabrese, JR ;
Keck, PE ;
Macfadden, W ;
Minkwitz, M ;
Ketter, TA ;
Weisler, RH ;
Cutler, AJ ;
McCoy, R ;
Wilson, E ;
Mullen, J .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (07) :1351-1360
[10]   Quetiapine - A review of its use in the management of schizophrenia [J].
Cheer, SM ;
Wagstaff, AJ .
CNS DRUGS, 2004, 18 (03) :173-199